Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 12/20 | 0.62 |
| ▸ | IDO1 | P14902 | 10/20 | 0.62 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.62 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.55 |
| ▸ | METAP1 | P53582 | 1/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1030506 | 0.78 | METAP2 (0.63) | METAP2IDO1KEAP1SIRT3METAP1 | |
| SCHEMBL8221447 | 0.77 | METAP2 (1.00) | METAP2IDO1KEAP1SIRT3METAP1 | |
| SCHEMBL8664138 | 0.75 | METAP2 (0.95) | METAP2IDO1KEAP1SIRT3METAP1 | |
| SCHEMBL297000 | 0.73 | IDO1 (0.31) | METAP2IDO1KEAP1 | |
| SCHEMBL294336 | 0.73 | AKT2 (0.59) | METAP2IDO1KEAP1 | |
| SCHEMBL1099384 | 0.72 | ADH5 (0.53) | IDO1 | |
| SCHEMBL610112 | 0.71 | ALDH1A1 (0.33) | — | |
| SCHEMBL29539786 | 0.71 | METAP2 (1.00) | METAP2IDO1KEAP1SIRT3METAP1 | |
| SCHEMBL28058540 | 0.71 | METAP2 (1.00) | METAP2IDO1KEAP1SIRT3METAP1 | |
| Methylamine SCHEMBL27801352 | 0.69 | AKT2 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642642-B2 | Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor | ABBOTT LABORATORIES (US) | 2014-02-04 | — | — | US | disclosed |
| US-8497273-B2 | Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor | ABBOTT GMBH & CO. KG (DE) | 2013-07-30 | — | — | US | disclosed |
| US-20100048582-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2010-02-25 | — | — | US | disclosed |
| US-20090306175-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2009-12-10 | — | — | US | disclosed |
| CN-101421234-A | Is suitable for treating p-hydroxytryptamine 5HT6Heterocyclic aryl sulfones of receptor-modulated responsive disorders | ABBOTT GMBH (DE) | 2009-04-29 | — | — | CN | disclosed |
| CN-101421264-A | Is suitable for treating serotonin 5HT6Heterocyclic compounds for receptor-modulated responsive disorders | ABBOTT GMBH & CO KG (DE) | 2009-04-29 | — | — | CN | disclosed |
| EP-2029528-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007118899-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306175-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | HTR6, HTR1A, HTR5A | METAP2 778/4885IDO1 405/4885KEAP1 2464/4885 |
| US-20100048582-A1 | HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | HTR6, HTR1A, HTR2C | METAP2 1094/4885IDO1 620/4885KEAP1 2740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.